1. ？Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med,2013,187:347-365.
[2]
2. Restrepo MI, Anzueto A. Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations:are we there yet? Am J Respir Crit Care Med,2014,190:1-2.
[3]
3. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol,2001,63:521-554.
[4]
4. Moreno D, Garcia A, Lema D, et al. Surfactant protein D in chornic obstructive pulmonary disease (COPD). Recent Pat Endocr Metab Immune Drug Discov,2014,8:42-47.
[5]
5. Miyagaki T, Sugaya M, Suga H, et al. Increased CCL18 expression in patients with cutaneous T-cell lymphoma:association with disease severity and prognosis. J Eur Acad Dermatol Venereol,2013,27:e60-67.
7. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2011,183:1187-1192.
[8]
8. Sin DD, Pahlavan PS, Man SF. Surfactant protein D:a lung specific biomarker in COPD? Ther Adv Respir Dis,2008,2:65-74.
[9]
9. Mazur W, Toljamo T, Ohlmeier S, et al. Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur Respir J,2011,38:277-284.
[10]
10. Johansson SL, Tan Q, Holst R, et al. Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage. Am J Physiol Lung Cell Mol Physiol,2014,306:L887-L895.
[11]
11. Fujita M, Shannon JM, Ouchi H, et al. Serum surfactant protein D is increased in acute and chronic inflammation in mice. Cytokine,2005,31:25-33.
[12]
12. Hirama N, Shibata Y, Otake K, et al. Increased surfactant protein-D and foamy macrophages in smoking-induced mouse emphysema. Respirology,2007,12:191-201.
[13]
13. Sims MW, Tal-Singer RM, Kierstein S, et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels:a cross-sectional study. Respir Res,2008,9:13.
[14]
14. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol,2005,78:14-26.
[15]
15. Kim HO, Cho SI, Chung BY, et al. Expression of CCL1 and CCL18 in atopic dermatitis and psoriasis. Clin Exp Dermatol,2012,37:521-526.
[16]
16. Kollert F, Probst C, Müller-Quernheim J, et al.CCL18 production is decreased in alveolar macrophages from cigarette smokers. Inflammation,2009,32:163-168.
[17]
17. Horváth I, Hunt J, Barnes PJ, et al. Exhaled breath condensate:methodological recommendations and unresolved questions. Eur Respir J,2005,26:523-548.
[18]
18. Davis MD, Montpetit A, Hunt J. Exhaled breath condensate:an overview. Immunol Allergy Clin North Am,2012,32:363-375.
[19]
19. Muller WG, Morini F, Eaton S, et al. Safety and feasibility of exhaled breath condensate collection in ventilated infants and children. Eur Respir J,2006,28:479-485.
[20]
20. Kubáň P, Foret F. Exhaled breath condensate:determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. Anal Chim Acta,2013,805:1-18.
